“Bronstein, Gewirtz & Grossman LLC Launches Investigation: Potential Business and Professional Services Misconduct Uncovered”

Investigation of PACS Group, Inc. Potential Claims Being Investigated New York, NY / ACCESS Newswire / February 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is currently conducting an investigation regarding potential claims on behalf of investors who purchased PACS Group, Inc. securities (NYSE:PACS) prior to April 11, 2024, and continue to hold the stocks…

Read More

Unlocking the Crypto World: A Chat with XYO Co-Founder Markus Levin on Data Control, UBI, and More!

Welcome to the Crypto Wonderland! Exploring the Exciting World of DePINs Hey there, fellow adventurers in the realm of digital currencies and blockchain technology! Today, we’re diving into the fascinating world of XYO, the world’s first and largest DePIN (Decentralized Proof of Information Network). If you’re not familiar with DePINs, don’t worry – we’ll break…

Read More

Get Ready to Ride the Crypto Wave: Whales are Stocking Up on These Coins for Big Gains in Q4 2024! Don’t Miss Out on DTX, Ripple, and Binance Coin!

Welcome to the Cryptocurrency Rollercoaster! Hold on tight as we dive into the wild world of crypto whales and altcoins Get ready for a thrill ride through Ripple, Binance Coin, and DTX Exchange Just like in other bull years, the cryptocurrency market is becoming more active in the final quarters, and the key players are…

Read More

Get Ready to Geek Out: Cardiff Oncology’s First-Line MCRC Data is Dropping Soon!

Welcome to the Blog Post! Let’s Talk About Cardiff Oncology’s Onvansertib and Its Potential Impact So, you may have heard about Cardiff Oncology’s latest breakthrough with Onvansertib in treating RAS-mutated metastatic colorectal cancer. If you haven’t, don’t worry, I’m here to fill you in on all the exciting details! Cardiff Oncology’s Onvansertib is causing quite…

Read More

InMed Signs Standby Equity Purchase Agreement

InMed Pharmaceuticals Announces Standby Equity Purchase Agreement Introduction Vancouver, British Columbia–(Newsfile Corp. – December 17, 2024) – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces it entered into a Standby Equity Purchase…

Read More